Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International randomized phase 3 trial in newly diagnosed Ewing sarcoma comparing VIDE versus VDC/IE strategies with a zoledronic acid randomization
NL-OMON50678Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide and 4 more in Ewing sarcoma and Ewing family of tumors (EFT) (4 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Event-free survival. Started Oct 2016; status: completed.
02
Drugs
vincristineifosfamidedoxorubicinetoposidecyclophosphamide
03
Conditions
Ewing sarcomaEwing family of tumors (EFT)
Beyond the preview
Go deeper on NL-OMON50678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50678.